All In Biotech

NDA 202806 · Novartis

Tafinlar

Dabrafenib Mesylate · Oral

NovelBreakthrough therapyAccelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

May 29, 2013

Approved uses

13

Original approval plus efficacy supplements

Registered trials

161

15 Phase 3, 27 recruiting

FAERS reports

21,157

15,709 serious, 4,427 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 20, 2026.

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known...

Mechanism: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC 50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC 50 values of 3.2 and 5.0 nM, respectively, and other kinases, such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [see Indications and Usage (1)] . Dabrafenib inhibits cell growth...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 7, 2025 Supplement 33 · Efficacy OrphanLetterLabel
  • Aug 31, 2023 Supplement 27 · Efficacy · priority review OrphanLetterLabel
  • Mar 16, 2023 Supplement 25 · Efficacy · priority review OrphanLabelLetter
  • Jun 22, 2022 Supplement 22 · Efficacy · priority review OrphanLabelLetter
  • May 27, 2022 Supplement 23 · Efficacy LetterLabel
  • Jan 28, 2022 Supplement 19 · Efficacy OrphanLetterLabel
  • Oct 6, 2019 Supplement 12 · Efficacy OrphanLabelLetter
  • May 4, 2018 Supplement 10 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Apr 30, 2018 Supplement 8 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jun 22, 2017 Supplement 6 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 20, 2015 Supplement 4 · Efficacy OrphanLetterLabel
  • Jan 9, 2014 Supplement 2 · Efficacy · priority review OrphanReviewLabelLetter
  • May 29, 2013 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLabelReviewSummary Review
2 products under this application
  • TAFINLAR · DABRAFENIB MESYLATE EQ 75MG BASE · CAPSULE, ORAL · Prescription
  • TAFINLAR · DABRAFENIB MESYLATE EQ 50MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dabrafenib" as an intervention, any sponsor and status, largest first.

All 161 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia4,146
  • death2,899
  • malignant neoplasm progression1,771
  • fatigue1,445
  • nausea1,414
  • chills1,343
  • rash1,189
  • vomiting995
  • diarrhoea988
  • headache750
  • asthenia733
  • malaise628

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
2013415
2014730
20151,704
20161,382
20171,636
20182,134
20192,338
20202,056
20212,057
20221,877
20231,774
20241,275
20251,103
2026675

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tafinlar (Dabrafenib Mesylate)

2024 spending

$174M

Beneficiaries

2,440

13,603 claims

Per beneficiary

$71,268

$111.52 per unit

View as table
YearSpending
2020$100,077,167
2021$117,905,873
2022$137,437,665
2023$146,891,650
2024$173,893,215

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 181 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.